Welcome to our dedicated page for Zimmer Biomet news (Ticker: ZBH), a resource for investors and traders seeking the latest updates and insights on Zimmer Biomet stock.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) is a global medical technology company focused on musculoskeletal health, orthopedic implants and digital and robotic technologies. This news page aggregates company announcements, press releases and market-facing updates so readers can follow how Zimmer Biomet develops and commercializes its orthopedic, trauma and digital care offerings.
Recent news highlights include earnings announcements and conference call webcasts, where Zimmer Biomet reports quarterly financial results and discusses performance across product categories such as knees, hips, sports medicine, extremities, trauma and technology and data, bone cement and surgical. The company also issues updates on its capital allocation, including quarterly cash dividends approved by its Board of Directors.
Zimmer Biomet frequently announces product and technology milestones. Examples include U.S. FDA 510(k) clearance for an enhanced version of its ROSA Knee robotic technology, FDA Breakthrough Device Designation for an iodine-treated total hip replacement system, and launches of new foot and ankle trauma solutions through its Paragon 28 business. The company also reports collaborations and integrations, such as the use of mobility intelligence technology within its mymobility care management platform, and highlights its broader connected care strategy linking robotics, digital platforms and analytics.
Investors and observers can also find updates on Zimmer Biomet’s participation in major healthcare and investor conferences, as well as news related to acquisitions like the merger with Monogram Technologies Inc. Bookmark this page to review the latest official communications from Zimmer Biomet on its orthopedic portfolio, digital and robotic technologies, financial disclosures and strategic initiatives.
Zimmer Biomet Holdings (NYSE: ZBH) announced that its Chairman, President and CEO Bryan Hanson and Executive Vice President and CFO Suky Upadhyay will present at Stifel's 2021 Virtual Healthcare Conference on November 17, 2021, at 10:40 a.m. Eastern Time. Investors can access a live webcast of the presentation through Zimmer Biomet's Investor Relations website. Zimmer Biomet is a global leader in medical technology, focused on enhancing mobility and health through innovative products and technologies.
Zimmer Biomet Holdings, Inc. (ZBH) will host its third quarter earnings conference call on November 4, 2021, at 8:30 a.m. ET, with a news release available at 6:30 a.m. ET. The call can be accessed on the company’s Investor Relations website and will feature digital recording availability from November 4 to December 31, 2021. Zimmer Biomet is recognized for its innovative medical technology aimed at enhancing patient mobility and healthcare quality.
Zimmer Biomet Holdings (NYSE: ZBH) announced key leadership appointments for its planned spin-off company, ZimVie, targeting the Spine and Dental businesses. Richard J. Heppenstall joins as Executive Vice President and CFO, bringing over 25 years of finance experience in the medtech sector. The spin-off is on track for mid-2022, aiming to enhance resource allocation and market leadership. The new leadership team includes seasoned professionals across various functions to drive ZimVie’s success post-separation.
Zimmer Biomet Holdings has declared a quarterly cash dividend of $0.24 per share for the third quarter of 2021. This dividend will be payable on October 29, 2021 to shareholders on record as of September 30, 2021. The company, a leader in medical technology, is known for its innovative solutions aimed at improving health and mobility. Zimmer Biomet operates globally, contributing to advancements in patient care through integrated digital and robotic technologies.
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) announced four presentations at the AAOS 2021 Annual Meeting showcasing the clinical value of mymobility with Apple Watch. This remote care management platform aids healthcare professionals in supporting patients pre- and post-orthopedic procedures. Initial findings from the ongoing mymobility Clinical Study suggest that patients using the platform experience similar outcomes to traditional care, potentially lowering postoperative costs. The conference is taking place from August 31 to September 3, 2021 in San Diego.
Zimmer Biomet Holdings (ZBH) announced that Chairman Bryan Hanson and CFO Suky Upadhyay will present at Baird's 2021 Virtual Global Healthcare Conference on September 14, 2021, at 10:50 a.m. ET. A live webcast of the presentation can be accessed via Zimmer Biomet's Investor Relations website. The company specializes in medical technology, focusing on enhancing patient mobility through innovative products and digital technologies. Zimmer Biomet operates in over 25 countries, with sales in more than 100 countries, and boasts over 90 years of industry experience.
Zimmer Biomet Holdings (NYSE: ZBH) has received FDA 510(k) clearance for its ROSA® Hip System, enhancing its robotic surgical portfolio. This system aids in robotically-assisted direct anterior total hip replacement, offering surgeons real-time data and control over surgical procedures. ROSA Hip integrates with ZBEdge and mymobility® technologies to improve patient outcomes and streamline surgical workflows. Designed for compatibility with various implant systems, it aims to enhance procedural efficiency and mitigate intra-operative variability.
Zimmer Biomet Holdings announced six key data presentations at the upcoming American Academy of Orthopaedic Surgeons (AAOS) 2021 Annual Meeting scheduled for August 31 to September 3 in San Diego. Highlights include a podium presentation of the investigational Persona IQ smart knee implant and three posters detailing the clinical utility of the mymobility remote care management platform. The company is set to showcase its latest technologies, including the ROSA Hip, which is currently under FDA review, as part of its ZBEdge Connected Intelligence suite.
Zimmer Biomet Holdings reported second-quarter 2021 net sales of $2.027 billion, a remarkable 65.3% increase from the previous year. Net earnings reached $141.9 million ($0.67 per share) with adjusted diluted EPS at $1.90. Compared to pre-pandemic Q2 2019, sales are up 1.9%. The company anticipates continued growth despite ongoing COVID-19 pressures. Zimmer Biomet has also updated its full-year 2021 guidance, projecting revenue growth of 14.5% - 16.5% and adjusted diluted EPS of $7.65 - $7.95.
ZBH will host its second quarter earnings conference call on August 3, 2021, at 8:30 a.m. ET. The financial results will be released earlier that day at 6:30 a.m. ET. Investors can access the live audio webcast on Zimmer Biomet's Investor Relations website, which will also be archived for later replay. U.S. participants can join the call by dialing (888) 312-9837 and entering the conference ID 7278985. This conference call follows Zimmer Biomet's ongoing commitment to transparency and communication with its investors.